1. Home
  2. |Insights
  3. |Deal Note: Crowell & Moring Client Integrated BioTherapeutics Enters Into Exclusive Agreement with Chembio Diagnostics to Develop POC Diagnostic Tests for Ebola

Deal Note: Crowell & Moring Client Integrated BioTherapeutics Enters Into Exclusive Agreement with Chembio Diagnostics to Develop POC Diagnostic Tests for Ebola

Firm News | less than 1 min read | 10.27.14

Washington, D.C. – October 27, 2014: Crowell & Moring, LLP is representing Integrated BioTherapeutics, Inc. (IBT), a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases, as it enters into an exclusive agreement with Chembio Diagnostics, Inc., a leader in point-of-care (POC) diagnostic tests for infectious diseases. Under the terms of the agreement, Chembio will combine its patented DPP technology with IBT's proprietary Ebola reagents to develop POC diagnostic tests for Ebola and febrile illness. Chembio will have exclusive rights to any POC product developed through this agreement. Financial terms of the agreement were not disclosed.

Insights

Firm News | 1 min read | 11.22.24

Crowell & Moring Represents Anitian in Successful $7M Series D Funding

San Francisco - November 22, 2024: Crowell & Moring advised Anitian, a leading provider of compliance automation solutions, on a $7 million Series D funding, led by Sageview Capital and with participation by Forgepoint Capital. This funding enables Anitian to accelerate the development of new innovations, including AI-driven automation features and an accredited Platform-as-a-Service (PaaS). Together, these features reduce the time and cost of achieving FedRAMP and CMMC compliance for Cloud Service Providers (CSPs) and the Defense Industrial Base (DIB). The most recent financing brings Anitian’s total funding to more than $50 million....